Abstract 5995
Background
The number of publications on the invasive fungal diseases caused by rare pathogens (rare IFD) after HSCT and chemotherapy is limited.
Methods
From 2008 to 2017 in R. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation (CIC725) have been performed 2738 HSCT including 1845 allogeneic (allo-HSCT) and 893 autologous HSCT (auto-HSCT). During the observation period 40 probable and proven rare IFD (EORTC/MSG 2008 criteria) cases were diagnosed in children and adults with hematological malignances and non-malignant hematological diseases after allo-HSCT (n = 30), auto-HSCT (n = 2), and chemotherapy (n = 8). The median follow up time for rare IFD cases was 3 months; for survivors – 30 months.
Results
Incidence of rare IFD in HSCT recipients was 1,5%, it was higher after allo-HSCT (1,6%) than auto-HSCT (0,2%) (p < 0,01). In 8 patients, this complication developed after CT and 4 of them proceed to allo-HSCT. The most frequent underlying diseases were ALL (33%) and acute AML (30%). The median time of onset of rare IFD after allo-HSCT - 104 (21-1057) days, auto-HSCT – 138 (60-216), after start of CT – 161 (79-189). Etiology of rare IFD was identified by culture in 65% cases: Rhizopus spp. – 27%, Paecilomyces spp. – 7%, Fuzarium spp. – 5%, Malassezia furfur – 5%, Trichosporon asahii – 3%, Scedosporium apiosperium – 2%, Scopulariopsis gracilis – 2%, Rhizomucor pusillus – 2%, Lichtheimia corymbifera – 2%, mix rare IFD with Rhizopus spp. + Paecilomyces spp. – 5%, Paecilomyces spp. + Fuzarium spp. – 5%. 35% cases were diagnosed by microscopy. Antifungal therapy was used in all patients: lipid amphotericin B (L-AmB) – 30%, L-AmB + caspofungin – 22,5%, voriconazole – 17,5%, posaconazole (posa) – 12,5%, L-AmB + posa – 10%, and echinocandins – 7,5%. Overall survival at 12 weeks from the diagnosis of rare IFD was 50%. The 12-weeks overall survival was better in patients after CT and auto-HSCT (80%) than allo-HSCT (42%), p = 0,048.
Conclusions
The incidence of rare IFD in HSCT recipients was 1,5%. Rare IFD is a late complication after chemotherapy and HSCT and usually develops after or in combination with invasive aspergillosis. Higher incidence and worst prognosis rare IFD is observed in allo-HSCT recipients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract